YOLFTbeta
32

TiumBio Co. Ltd

321550 · KQ · Healthcare / Biotechnology

3,465.00KRW-220.00 (-5.97%)

Price History

Full chart

Market Stats

Previous Close3,685.00
Open3,690.00
Day Range3,465.00 – 3,870.00
52-Week Range3,415.00 – 13,700.00
Volume104.10K
Market Cap133.05B
P/E (TTM)0.00
Forward P/E0.00
Dividend Yield0.00%
Beta-0.46
50-Day Avg4,439.10
200-Day Avg6,440.58

About

TiumBio Co., Ltd., a drug discovery company, researches and develops therapeutics for patients with unaddressed rare diseases. The company's products pipeline includes chemical entity-based drugs and biopharmaceuticals comprising NCE401, NCE403, NCE406, and NBP604. It has a collaboration agreement with Oncodesign Société Anonyme for the research and development of fibrosis drug candidates. The company was founded in 2016 and is based in Seongnam-si, South Korea.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Huntaek Kim
  • Employees68
  • Headquarters30, Changup-ro 40beongil, Seongnam-si, South Korea, 13493, Korea
  • Websitehttps://www.tiumbio.com

Leadership

  • Mr. Huntaek KimChief Executive Officer · b. 1966
  • Ms. Hyunsil KohChief Financial Officer

Financials

Income Statement

Currency: KRW2017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue225.50M1.13B1.11B1.05B56.80M9.12B4.90B6.79B12.29B
Growth (%)-+400.62%-1.41%-5.75%-94.59%+15952.75%-46.27%+38.65%+80.92%
Cost of Revenue-------4.84B7.24B
Gross Profit---1.05B56.80M9.12B4.90B6.79B5.04B
Gross Margin---100.00%100.00%100.00%100.00%100.00%41.05%
Operating Expense---14.35B32.75B34.08B20.94B12.14B21.18B
Operating Income-4.24B-5.24B-8.02B-13.30B-32.70B-24.96B-16.04B-5.34B-16.14B
Operating Margin-1881.76%-464.26%-720.54%-1268.26%-57566.15%-273.74%-327.43%-78.67%-131.33%
EBITDA------27.12B-13.31B-15.70B-9.66B
EBITDA Margin------297.47%-271.76%-231.21%-78.59%
Net Income-8.79B-13.75B-7.09B-12.12B-31.64B-29.85B-17.91B-20.64B-17.36B
Net Income Margin-3900.17%-1218.14%-637.15%-1155.33%-55701.69%-327.42%-365.62%-303.93%-141.27%
R&D---9.83B25.80B21.29B17.87B9.48B9.67B
R&D as % of Total Revenue---937.16%45426.97%233.48%364.73%139.58%78.68%
Interest Expense00040.84M518.46M808.36M2.47B4.04B5.45B
Interest Expense % of Total Revenue0.00%0.00%0.00%3.89%912.81%8.87%50.44%59.53%44.37%

Balance Sheet

Currency: KRW2017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets10.12B29.32B93.46B85.35B116.73B96.26B119.55B107.30B98.55B
Total Liabilities17.21B574.77M958.28M2.84B29.16B35.22B49.17B54.83B60.81B
Total Equity-7.09B28.75B92.50B82.51B87.57B61.04B70.08B52.47B40.80B
Cash2.27B1.86B16.88B3.46B365.00K609.00K10.51B788.00K10.76B
Total Debt---931.16M-----
Net Debt----10.91B3.71B17.02B12.91B19.74B

Cash Flow

Currency: KRW2017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-3.61B-5.05B-4.45B-9.38B-24.80B-16.01B-20.62B-15.63B-15.30B
Investing Cash Flow-7.77B-18.86B-64.15B9.57B-24.79B24.39B-9.63B24.68B-
Financing Cash Flow13.65B23.50B69.62B598.10M53.02B2.78B22.98B-2.75B-
Capital Expenditure3.46B236.68M503.39M867.17M11.84B11.19B18.36B1.04B382.16M
Free Cash Flow----10.27B-36.69B-27.33B-38.98B-16.67B-15.68B
FCF to OCF---109.54%147.94%170.70%189.06%106.69%102.50%

Earnings

Report DateMar 31, 2020Jun 30, 2020Sep 30, 2020Dec 31, 2020Mar 31, 2021Jun 30, 2021Sep 30, 2021Mar 31, 2022Jun 30, 2022Sep 30, 2022Dec 31, 2022Mar 31, 2023Jun 30, 2023Sep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
EPS Estimate-------------------------
EPS Actual-88.20-137.84-155.68-134.24-152.17-403.95-301.82-175.53-510.44-179.67-380.26-328.60-582.0012.00158.48-293.74-487.37-161.22137.11-295.66-77.00-200.24-67.84-185.98-143.29
Surprise-------------------------
Timing-------------------------

Key Statistics & Ratios

Market Cap133.05B
Enterprise Value130.30B
Trailing P/E0.00
Forward P/E0.00
Price / Sales8.87
Price / Book3.82
Revenue (TTM)15.00B
Gross Profit (TTM)5.92B
EBITDA-12.54B
Profit Margin-114.10%
Operating Margin-94.81%
Return on Equity-36.65%
Return on Assets-10.05%
Shares Outstanding29.40M
Shares Float20.00M
Beta-0.46
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%